Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lifshitz & Miller Law Firm Announces Investigation of Electronics for Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., and TG Therapeutics, Inc.

TGTX, HUM, FSPM, PBYI, FIZZ, ZVRA, FGPR, EFII

PR Newswire

NEW YORK, Oct. 31, 2016 /PRNewswire/ --

Electronics for Imaging, Inc. (EFII)

Lifshitz & Miller announces investigation on behalf of EFII investors.  The investigation concerns whether EFII adequately disclosed its earnings, projections and price targets.

If you are an EFII investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Ferrellgas Partners LP (FGP)

Lifshitz & Miller announces investigation on behalf of FGP investors.  The investigation concerns FGP's reporting of poor earnings in its 2015 annual report and that FGP may reduce the annual distribution to shareholders by more than half.

If you are an FGP investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Fusion Pharm, Inc. (FSPM)

Lifshitz & Miller announces investigation on behalf of Fusion investors.  The investigation concerns whether Fusion inflated FSPM's revenues for purported sales of PharmPods.

If you are a FSPM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Humana Inc. (HUM)

Lifshitz & Miller announces investigation on behalf of Humana investors.  The investigation concerns whether Humana adequately disclosed Humana's membership percentage in plans rated four stars or higher.

If you are a Humana investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

KemPharm, Inc. (KMPH)

Lifshitz & Miller announces investigation on behalf of KMPH investors.  The investigation concerns whether KMPH adequately disclosed material information about Apadaz.

If you are a KMPH investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

National Beverage Corp. (FIZZ)

Lifshitz & Miller announces investigation on behalf of FIZZ investors.  The investigation concerns a report by Glaucus Research, which alleged that FIZZ's former CEO manipulated earnings, refused to provide adequate due diligence for a potential acquirer, and that insiders are compensated from a private corporation, outside of shareholder visibility.

If you are an FIZZ investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Puma Biotechnology, Inc. (PBYI)

Lifshitz & Miller announces investigation on behalf of Puma investors.  The investigation concerns whether Puma adequately disclosed the efficacy for Puma's drug candidate Neratinib.

If you are a Puma investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

TG Therapeutics, Inc. (TGTX)

Lifshitz & Miller announces investigation on behalf of TGTX investors.  The investigation concerns whether TGTX adequately disclosed TGTX's GENUINE study.

For additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ATTORNEY ADVERTISING. © 2016 Lifshitz & Miller.  The law firm responsible for this advertisement is Lifshitz & Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz & Miller
Phone:  516-493-9780
 
Facsimile: 516-280-7376
Email: info@jlclasslaw.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lifshitz--miller-law-firm-announces-investigation-of-electronics-for-imaging-inc-ferrellgas-partners-lp-fusion-pharm-inc-humana-inc-kempharm-inc-national-beverage-corp-puma-biotechnology-inc-and-tg-therapeutics--300354094.html

SOURCE Lifshitz & Miller Law Firm



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today